Clo­vis shut­ters PhII Rubra­ca study af­ter da­ta mon­i­tors turn thumbs down on ef­fi­ca­cy

Still strug­gling to find ways to ex­pand its on­col­o­gy fran­chise for Rubra­ca, Clo­vis qui­et­ly re­vealed af­ter the mar­ket closed Fri­day that it is shut­ter­ing a monother­a­py Phase II study in blad­der can­cer af­ter in­de­pen­dent ob­servers con­clud­ed that the PARP drug wasn’t go­ing to win this one.

The DMC sug­gest­ed re­searchers stop re­cruit­ing new pa­tients and Clo­vis $CLVS de­cid­ed to ter­mi­nate it al­to­geth­er. Safe­ty, the com­pa­ny added in the SEC fil­ing, was not a fac­tor.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER